Untitled.jpg
AGBA Announces Fourth Quarter 2023 Earnings, Amid Challenging Macro Environment.
March 28, 2024 16:10 ET | AGBA Group Holding Ltd
HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial...
CEA logo.png
CEA Industries Inc. Reports Fourth Quarter and Full Year 2023 Results
March 28, 2024 16:10 ET | CEA Industries Inc.
Louisville, Colorado, March 28, 2024 (GLOBE NEWSWIRE) -- CEA Industries Inc. (NASDAQ: CEAD, CEADW) (“CEA Industries” or the “Company”), is reporting results for the three and twelve months ended...
Forian Logo - NewMediaWire.jpg
Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024 16:06 ET | Forian Inc.
Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Forian Inc. (Nasdaq: FORA), a provider of...
RM Primary Logo - Humble.png
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
March 28, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
fortressbio1.jpg
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
March 28, 2024 16:05 ET | Fortress Biotech, Inc.
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application...
tpi_logo_release_v01_01_color.png
TPI Composites, Inc. Publishes its Annual Sustainability Report Reaffirming Its Commitments to a Zero-Harm Culture and Carbon Neutrality
March 28, 2024 16:05 ET | TPI Composites, Inc.
SCOTTSDALE, Ariz., March 28, 2024 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (Nasdaq: TPIC), today published its 2023 sustainability report highlighting its progress on organizational and global...
Logo_EnlivenTherapeutics.png
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
March 28, 2024 16:05 ET | Enliven Therapeutics, Inc.
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
logo (2).jpg
ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer
March 28, 2024 16:05 ET | ASML Netherlands BV
ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer VELDHOVEN, the Netherlands, March 28, 2024 – ASML Holding NV (ASML) today announced that it recently became aware of an...
SELLAS Logo.png
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 16:05 ET | SELLAS Life Sciences Group, Inc.
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
March 28, 2024 16:05 ET | Assembly Biosciences, Inc.
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating...